Radical reforms to China’s IP system are set to benefit pharma and biotech patentees, but several key questions remain unanswered
Reset password
Register to access two of our subscriber only articles per month.
Register
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe
Author | Life sciences reporter
[email protected]
@IAM_Alerts Potentially very big news - the IEEE is reviewing its controversial patent policy, six years after it was changed i… https://t.co/yRnFwbX8Cl Read more
@IAM_Alerts Given new opportunities for monetisation, entities involved in healthcare research must have a strategy for protect… https://t.co/BG93bhHxyU Read more
@IAM_Alerts Intellectual Ventures has rolled out a new licensing programme focused on Chinese SMEs. Details on pricing, terms a… https://t.co/nrCi3LEi10 Read more
@IAM_Alerts Ericsson says Chinese court's anti-suit order amounts to 'forced technology transfer' - full details of the latest… https://t.co/rF2kr3kZ9a Read more
